Early and Late Histological and Ultrastructural Findings in Resected Infantile Capillary Hemangiomas Following Treatment with Topical Beta-Blocker Timolol Maleate 0.5%

Background: Infantile capillary hemangiomas (IHs) affect approximately 4-5% of infants. The systemic nonselective β-adrenergic antagonist, propranolol, has become the standard first-line treatment for severe IHs. The topical β-antagonist, timolol maleate, has also demonstrated efficacy and safety in treating superficial and some deep capillary hemangiomas. Despite their therapeutic success and prevalent use, the mechanism of action of β-adrenergic antagonists in the treatment of IHs is not well understood. Methods: Histopathological and electron microscopic evaluation of two periocular IHs excised at 1 week and 24 months following topical timolol treatment was performed. Results: Distinct morphological differences were observed between spontaneously regressed and β-antagonist-treated IHs. The former was characterized by diffuse collagen deposition and interstitial fibrosis, while the latter showed organized concentric collagen IV deposition within obliterated vessel lumen, suggestive of waves of endothelial cell apoptosis, leaving behind layers of basement membrane deposits as a stress response. Conclusions: Based on these observations, we hypothesize that, apart from their well-known cardiac and vasodilatory effects, β-antagonists could induce endothelial cell apoptosis in IH leading to endovascular occlusion and we present supporting evidence to explain why this response might be specific to hypoxic tissue.

[1]  G. D. Hildebrand,et al.  Topical timolol maleate 0.5% solution for the management of deep periocular infantile hemangiomas. , 2016, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus.

[2]  G. D. Hildebrand,et al.  Review of topical beta blockers as treatment for infantile hemangiomas. , 2016, Survey of ophthalmology.

[3]  P. Bagnoli,et al.  Infantile Hemangiomas, Retinopathy of Prematurity and Cancer: A Common Pathogenetic Role of the β‐Adrenergic System , 2015, Medicinal research reviews.

[4]  D. Day,et al.  Increased apoptosis and secretion of tryptase by mast cells in infantile haemangioma treated with propranolol , 2014, Pathology.

[5]  K. Xue,et al.  Deep periocular infantile capillary hemangiomas responding to topical application of timolol maleate, 0.5%, drops. , 2013, JAMA ophthalmology.

[6]  Min Zhang,et al.  Regulation of glucose transporter protein-1 and vascular endothelial growth factor by hypoxia inducible factor 1α under hypoxic conditions in Hep-2 human cells. , 2012, Molecular medicine reports.

[7]  K. Xue,et al.  Topical timolol maleate 0.5% for infantile capillary haemangioma of the eyelid , 2012, British Journal of Ophthalmology.

[8]  R. Rowntree,et al.  Propranolol treatment of infantile hemangioma endothelial cells: A molecular analysis , 2012, Experimental and therapeutic medicine.

[9]  A. Gosain,et al.  Propranolol Induces Regression of Hemangioma Cells Through HIF-1&agr;–Mediated Inhibition of VEGF-A , 2012, Annals of surgery.

[10]  C. Shields Topical Treatment for Capillary Hemangioma of the Eyelid Using β-Blocker Solution , 2011 .

[11]  P. Hoeger,et al.  Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action , 2010, The British journal of dermatology.

[12]  N. Dhalla,et al.  Mechanisms of the beneficial effects of beta-adrenoceptor antagonists in congestive heart failure. , 2010, Experimental and clinical cardiology.

[13]  I. Frieden,et al.  Infantile hemangiomas: an emerging health issue linked to an increased rate of low birth weight infants. , 2008, The Journal of pediatrics.

[14]  F. Boralevi,et al.  Propranolol for severe hemangiomas of infancy. , 2008, The New England journal of medicine.